• NTIASD2 Phase II/III clinical trial met the primary endpoint of a statistically significant improvement in severity of illness (CGI-S) at 8 weeks between NTI164 and placebo (p<0.001)
• Children in NTI164 group re-classified from markedly-severely ill (CGI-S: 5.54) at baseline to mild-moderately ill (CGI-S: 3.77) at 8 weeks, a very strong improvement
Seems like great results,
As well as an important product,
That can improve the lives of many people.
As well as having a considerable market size....
One would think some Big Pharma Co's would be sizing this up !!!!
